medac
medac is a German family-owned pharmaceutical company whose alkylating agent treosulfan, long used in Europe, was approved by the FDA in 2025 as conditioning treatment before stem cell transplantation in acute myeloid leukaemia and myelodysplastic syndromes.
Overview
medac GmbH, based in Wedel near Hamburg, is a privately held German company specialising in haematology, oncology, urology and autoimmune disease. Its alkylating agent treosulfan, approved in Europe for decades and marketed there as Trecondi for transplant conditioning, received FDA approval in January 2025 (Grafapex) with fludarabine as a preparative regimen before allogeneic haematopoietic stem cell transplantation in adults and children with acute myeloid leukaemia or myelodysplastic syndromes. Company facts are from the official website and FDA approval records.
Scorecard
All companies- approved products +6
- modalities +2
- regions +3
- registry trials +14
Similar pages
not linked directly; found by shared links- CompanyGamida Cell
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag fda-oce-applicant.
- CompanyGeron Corporation
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag fda-oce-applicant.
- CompanyOrca Biosystems
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- CompanyTreadwell Therapeutics
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- PersonMarc H.G.P. Raaijmakers
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- PersonUwe Platzbecker
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- TreatmentDorocubicel (UM171-expanded cord blood)
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- PersonPierre Fenaux
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.